OTCMKTS:BTCY Biotricity - BTCY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biotricity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.46 -0.02 (-4.17%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.45▼$0.5250-Day Range$0.46▼$0.8852-Week Range$0.40▼$2.48Volume183,987 shsAverage Volume68,301 shsMarket Capitalization$24.15 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort Interest Biotricity MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside552.2% Upside$3.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.38) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 stars 3.3 Analyst's Opinion Consensus RatingBiotricity has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Biotricity has a forecasted upside of 552.2% from its current price of $0.46.Amount of Analyst CoverageBiotricity has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for BTCY. Previous Next 0.0 Dividend Strength Dividend YieldBiotricity does not currently pay a dividend.Dividend GrowthBiotricity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BTCY. Previous Next 1.3 News and Social Media Coverage News SentimentBiotricity has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.Search InterestOnly 3 people have searched for BTCY on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Biotricity to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biotricity insiders have not sold or bought any company stock.Percentage Held by Insiders20.46% of the stock of Biotricity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.83% of the stock of Biotricity is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biotricity are expected to grow in the coming year, from ($0.38) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biotricity is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biotricity is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Biotricity (OTCMKTS:BTCY) StockBiotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. It is also involved in delivering remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The firm's FDA-approved Bioflux MCT technology is comprised of monitoring device and software components, which are made available to the market to assess, establish and develop sales processes, and market dynamics. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.Read More Receive BTCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotricity and its competitors with MarketBeat's FREE daily newsletter. Email Address BTCY Stock News HeadlinesMarch 7, 2023 | finance.yahoo.comMedical Biometric Firm Biotricity Reshaping Market Through Pioneering InnovationFebruary 16, 2023 | finance.yahoo.comBiotricity, Inc. (NASDAQ:BTCY) Q3 2023 Earnings Call TranscriptMarch 26, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastFebruary 16, 2023 | finance.yahoo.comBiotricity Third Quarter 2023 Earnings: Revenues Beat ExpectationsFebruary 14, 2023 | finance.yahoo.comBiotricity Reports Financial Results for Fiscal 2023 Third QuarterFebruary 9, 2023 | finance.yahoo.comBiotricity To Host Fiscal 2023 Third Quarter Financial Results Call on February 14th at 4:30pm ETFebruary 3, 2023 | finance.yahoo.comBiotricity Selected to Present its Work on AI Enabled Stroke Prediction in CKD Patients at the 2nd Annual Innovation Showcase during the American Stroke Association 2023 International Stroke ConferenceJanuary 26, 2023 | finance.yahoo.comBiotricity Signs Distribution Agreement With Top 5 Distributor for its Cardiac Monitoring SolutionsMarch 26, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastJanuary 23, 2023 | finance.yahoo.comBiotricity to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, January 25th at 8:15 A.M. ETDecember 12, 2022 | finance.yahoo.comBiotricity Files FDA 510(k) for a new Form Factor of its Biotres Cardiac Monitoring Device to Expand its Revenue GrowthDecember 12, 2022 | finance.yahoo.comBiotricity Files FDA 510(k) For Expanded Use Of Its Biotres Cardiac Monitoring DeviceDecember 9, 2022 | reuters.comBTCY.O - Biotricity Inc | Stock Price & Latest News | ReutersNovember 16, 2022 | finance.yahoo.comBiotricity Signs Distribution Agreement to Expand Access for its Cardiac Monitoring SolutionsNovember 10, 2022 | finance.yahoo.comBiotricity's Bioheart Named to TIME's List of The Best Inventions of 2022November 1, 2022 | finance.yahoo.comBiotricity to Host Fiscal 2023 Second Quarter Financial Results on November 14th at 4:30 PM ETOctober 26, 2022 | finance.yahoo.comBiotricity Launches Cardiac Disease Management Solution Following 2 Successful Pilots with Oklahoma & Kentucky ClinicsOctober 13, 2022 | finance.yahoo.comBiotricity CEO, Waqaas Al-Siddiq, to Participate in Panel Discussion on the Evolution of Medical Devices at the American Medical Device Summit on October 19thOctober 12, 2022 | businesswire.comThe Global Market for Wearable Electronic Skin Patches 2023-2033 - ResearchAndMarkets.com - Business WireOctober 7, 2022 | finance.yahoo.comFUKUI COMPUTER Partners with Bentley Systems to Promote Digital Transformation in Japan’s Infrastructure Field - Yahoo FinanceOctober 7, 2022 | finance.yahoo.comShareholders have faith in loss-making Biotricity (NASDAQ:BTCY) as stock climbs 18% in past week, taking three-year gain to 90%October 4, 2022 | finance.yahoo.comBiotricity Surpasses 2 billion Recorded and Analyzed Heartbeats for Atrial Fibrillation (AFib)September 15, 2022 | streetinsider.comDiagnostic Electrocardiograph Market to hit US$ 14.83 Billion by 2030 | Exclusive Report by Growth Plus Reports - StreetInsider.comSeptember 7, 2022 | globenewswire.comSmart Pregnancy Tracker Market is estimated to be US$ 13.2 Billion by 2020 with a CAGR of 17.4% during the forecast period 2030 - By PMI - GlobeNewswireSeptember 7, 2022 | finance.yahoo.comBiotricity Wins NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled Real-Time Monitoring and Predictive Analytics for Stroke due to Chronic Kidney Failure - Yahoo FinanceSeptember 7, 2022 | finance.yahoo.comBiotricity Wins NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled Real-Time Monitoring and Predictive Analytics for Stroke due to Chronic Kidney FailureSeptember 5, 2022 | businesswire.comGlobal External Remote Patient Monitoring Devices Pipeline Report 2022: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies - ResearchAndMarkets.com - Business WireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BTCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotricity and its competitors with MarketBeat's FREE daily newsletter. Email Address BTCY Company Calendar Last Earnings2/14/2023Today3/26/2023Fiscal Year End3/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BTCY CUSIPN/A CIK1630113 Webwww.biotricity.com Phone(650) 832-1626FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+552.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,130,000.00 Net Margins-220.94% Pretax Margin-216.64% Return on Equity-6,795.29% Return on Assets-183.66% Debt Debt-to-Equity RatioN/A Current Ratio0.66 Quick Ratio0.39 Sales & Book Value Annual Sales$7.70 million Price / Sales3.14 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-11.50Miscellaneous Outstanding Shares52,510,000Free Float41,770,000Market Cap$24.15 million OptionableNot Optionable Beta2.44 Key ExecutivesWaqaas Al-SiddiqChairman, President & Chief Executive OfficerJohn AyanoglouChief Financial OfficerSpencer LaDowVice President-EngineeringAmir AliChief Development OfficerKey CompetitorsVapothermNYSE:VAPOSeaStar MedicalNASDAQ:ICUNeuroOne Medical TechnologiesNASDAQ:NMTCLENSARNASDAQ:LNSRAcutus MedicalNASDAQ:AFIBView All CompetitorsInstitutional OwnershipSimplex Trading LLCBought 400 shares on 2/2/2023Ownership: 0.000%View All Institutional Transactions BTCY Stock - Frequently Asked Questions Should I buy or sell Biotricity stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biotricity in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BTCY shares. View BTCY analyst ratings or view top-rated stocks. What is Biotricity's stock price forecast for 2023? 2 brokerages have issued 12 month price targets for Biotricity's stock. Their BTCY share price forecasts range from $2.00 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 552.2% from the stock's current price. View analysts price targets for BTCY or view top-rated stocks among Wall Street analysts. How have BTCY shares performed in 2023? Biotricity's stock was trading at $0.4480 at the beginning of the year. Since then, BTCY stock has increased by 2.7% and is now trading at $0.46. View the best growth stocks for 2023 here. How were Biotricity's earnings last quarter? Biotricity, Inc. (OTCMKTS:BTCY) announced its earnings results on Tuesday, February, 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). The company had revenue of $2.46 million for the quarter, compared to the consensus estimate of $2.80 million. Biotricity had a negative trailing twelve-month return on equity of 6,795.29% and a negative net margin of 220.94%. What other stocks do shareholders of Biotricity own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biotricity investors own include Axsome Therapeutics (AXSM), Bank of America (BAC), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Broadcom (AVGO), Cannabix Technologies (BLOZF), BioLineRx (BLRX), CV Sciences (CVSI) and Charlotte's Web (CWBHF). What is Biotricity's stock symbol? Biotricity trades on the OTCMKTS under the ticker symbol "BTCY." Who are Biotricity's major shareholders? Biotricity's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Biotricity? Shares of BTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biotricity's stock price today? One share of BTCY stock can currently be purchased for approximately $0.46. How much money does Biotricity make? Biotricity (OTCMKTS:BTCY) has a market capitalization of $24.15 million and generates $7.70 million in revenue each year. The company earns $-29,130,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. How can I contact Biotricity? The official website for the company is www.biotricity.com. The company can be reached via phone at (650) 832-1626 or via email at investors@biotricity.com. This page (OTCMKTS:BTCY) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.